Emyria (formerly Emerald Clinics) and Zelira Therapeutics have inked a deal to collect data from Emyria patients using Zelira’s cannabinoid-based Zenivol medicine to treat insomnia.
Under the arrangement, de-identified patient data including diagnosis, co-morbidities, concomitant medications, dosage and responses to Zenivol will be assessed using clinical and subjective endpoints including the Insomnia Severity Index (ISI) questionnaire.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.